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Abstract 
Background 
Second-line treatment with irinotecan for advanced or metastatic colorectal cancer 
prolongs survival. It is uncertain whether irinotecan is better administered with 5-
fluorouracil or alone in patients previously treated with a fluoropyrimidine. We compared 
toxicity (particularly diarrhoea), quality of life, and efficacy of combination 
chemotherapy and irinotecan in these patients. 
Methods 
In DaVINCI, a randomised phase II trial, patients with advanced colorectal cancer were 
randomly allocated to: combination therapy (FOLFIRI), irinotecan (180 mg/m2 IV over 
90 min, day 1), 5-fluorouracil (400 mg/m2 IV bolus and 2400 mg/m2 by 46-hour infusion 
from day 1) and folinic acid (20 mg/m2 IV bolus, day 1), 2-weekly; or single-agent, 
irinotecan (350 mg/m2 IV over 90 min), 3-weekly. Toxicity was evaluated every 
treatment cycle; QOL and response 6 weekly. Analysis was by intention to treat. Results 
were also combined with those of other trials. 
Findings 
We randomised 44 patients to combination and 45 to single-agent. The most common 
toxicity was complete alopecia (single-agent 37%, combination 14%, P<0.02). Eight 
patients in the irinotecan arm and 4 in the combination arm had grade 3–4 diarrhoea 
(P=0.24).  The treatment groups did not differ significantly in overall QOL changes, 
response rate, or progression free or overall survival. In a systematic review of 29 trials 
of second-line irinotecan-based treatment, single-agent irinotecan was associated with 
more diarrhoea and alopecia than the combination, but efficacy was similar. 
Interpretation 
Combination treatment compared with single-agent irinotecan appears to reduce the rate 
of complete alopecia and diarrhoea without compromising efficacy on clinical outcomes.   
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Background 
Systemic therapy for advanced or metastatic colorectal cancer has advanced in the last 10 
years  1New active drugs include the cytotoxic agents, oxaliplatin and irinotecan, and the 
molecular targeting agents, bevacizumab, cetuximab, and panitumumab.  As first-line 
treatment, chemotherapy with 5-fluorouracil and folinic acid or capecitabine combined 
with either oxaliplatin or irinotecan plus bevacizumab results in median survival of 20–24 
months. 2-4 
The epidermal growth-factor receptor (EGFR) inhibitors, such as cetuximab, increase 
survival of patients with colorectal tumours expressing wild-type but not mutant K-ras 
genotype 5 The use of these agents in combination with chemotherapy is a favoured 
approach after failure of first-line schedules6 
Optimum second-line chemotherapy options have not been fully defined.  The 
combination of oxaliplatin and the fluoropyrimidine, 5-fluorouracil, with leucovorin in 
the FOLFOX regimen is superior to oxaliplatin alone in second-line treatment in terms of 
response rate and survival, albeit with some increase in toxicity.7 Second-line irinotecan 
and the combination of irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) improve 
survival over best supportive care or 5-fluorouracil infusion alone.8-11  However it is not 
clear whether FOLFIRI is preferable to irinotecan as second-line treatment.  Most 
patients receiving second-line therapy have been treated with 5-fluorouracil or 
capecitabine, and hence it could be argued that the use of 5-fluorouracil combined with 
irinotecan may add nothing in terms of efficacy but potentially increase toxicity.  
Alternatively, the combination of 5-fluorouracil and irinotecan was associated with less 
diarrhoea than irinotecan alone in the pivotal study (Saltz et al), suggesting that altered 
scheduling of irinotecan in combination with 5-fluorouracil may ameliorate the acute 
toxicity of weekly or 3-weekly irinotecan. 
Our study was designed to compare the toxicity, quality of life and efficacy of 
chemotherapy for patients with previously treated advanced colorectal cancer randomly 
assigned to 2-weekly schedules of FOLFIRI or single-agent irinotecan every 3 weeks. 
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Methods 
This trial was an investigator-initiated phase II trial sponsored by the Australasian 
Gastro-Intestinal Trials Group (AGITG) and was registered on the Australian New 
Zealand Clinical Trials Registry, ACTR 12605000359639. 
Study design 
The trial was originally designed as a 22 factorial study assessing (1) FOLFIRI 
compared with single-agent irinotecan and (2) celecoxib compared with placebo to assess 
impacts on quality of life and tumour response in 300 patients. The celecoxib arms were 
abandoned before the study began due to safety concerns about COX-2 inhibitors.12 
Patients were recruited from 17 sites in Australia and New Zealand. The protocol 
conformed to the Declaration of Helsinki and was approved by human research ethics 
committees at all participating institutions. All patients gave written informed consent. 
Recruitment was slower than expected and the protocol was amended in June 2007 to a 
randomised phase II trial to compare rates of toxicity in 100 patients. The primary 
outcome was the rate of grade 3 or 4 diarrhoea. Secondary outcomes were rates of other 
grade 3 or 4 toxicities, patient-reported quality of life, tumour response rates, 
progression-free survival and overall survival. 
To be eligible, patients were required to have histologically confirmed incurable locally 
advanced or metastatic colorectal cancer and at least one measurable lesion. Patients were 
18 years of age or older, and had a life expectancy of at least 12 weeks, ECOG 
performance status 0–2, and disease which had progressed after at least one 
chemotherapy regimen for advanced disease or adjuvant therapy within the previous 6 
months. Required pre-treatment haematological parameters were: haemoglobin >10 g/dL, 
white blood count >4.0109/L, neutrophils >1.5109/L, and platelets >100109/L. 
Pretreatment biochemical tests were required to show: serum creatinine <2.0 institution 
upper limit of normal (iULN) and bilirubin <1.5 iULN. Patients were required to be 
geographically accessible for follow-up and treatment. 
Patients were excluded if they had: evidence of serious infection or intercurrent illness 
that would prevent assessment of response and toxicity, previous chemotherapy or 
extensive radiotherapy within 4 weeks of the start of treatment, cerebral metastases, a 
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history or biochemical evidence of Gilbert’s syndrome, or prior therapy with irinotecan; 
or if they were pregnant or breast feeding. 
Randomisation and stratification 
The study was co-ordinated by the National Health and Medical Research Council 
Clinical Trials Centre, University of Sydney.  Patients were randomised centrally by 
telephone using the method of minimisation and stratified according to the presence or 
absence of liver metastases, ECOG performance status (0, 1 vs 2), institution and, after 
the 2007 amendment, time to progression after previous chemotherapy (<6 months or ≥6 
months). 
Trial therapies 
Treatment was to commence within 7 days of randomisation. Irinotecan as a single agent 
was administered at a dose of 300 or 350 mg/m2 (the lower dose was permissible for 
patients with ECOG 2 or if there were concerns about prior pelvic radiotherapy) by 
intravenous infusion over 90 minutes on day 1 and repeated on a 3-weekly schedule.  
Patients in the combination-therapy arm received a 2-weekly regimen of: irinotecan, 180 
mg/m2, by intravenous infusion over 90 minutes on day 1; 5-fluorouracil, 400 mg/m2, by 
intravenous bolus on day 1 followed by 2400 mg/m2 in a 46-hour infusion; and folinic 
acid (leucovorin), 20 mg/m2, by intravenous bolus.  Trial therapies were discontinued on 
progressive disease or excessive toxicity or if requested by the patient or physician. 
Study assessments 
Toxicity was evaluated at every treatment cycle and within 30 days of the last treatment 
cycle. Quality of life was measured at baseline and every 6 weeks with the European 
Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 
(EORTC QLQ) C-30, version 3.013, and the Patient Disease and Treatment Assessment 
(DATA) form.14.. Response was assessed every 6 weeks and classified according to 
RECIST 1.0.15 
Dose modification 
Single-agent irinotecan dose was reduced by 25% if grade 3 or 4 toxicity occurred and 
further reduced by 25% (relative to day 1 dose of the previous cycle) on a second episode. 
If further severe toxicity occurred, study treatment was discontinued. 
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In the combination-treatment arm, if grade 3 or 4 toxicity occurred, the irinotecan dose 
was reduced to 135 mg/m2 and the 5-fluorouracil bolus dose was reduced to 200 mg/m2.  
The infusional 5-fluorouracil and folinic acid doses were not changed. On a second 
episode, the irinotecan dose was reduced to 90 mg/m2 and the 5-fluorouracil infusion to 
1800 mg/m2, the bolus dose of 5-fluorouracil was omitted and the folinic acid dose 
remained unchanged. 
A new cycle of treatment could begin when the absolute neutrophil count was ≥1.509/L, 
the platelet count ≥75109/L and any treatment-related diarrhoea had returned to grade 0.  
Otherwise, treatment was delayed for 1 week until these conditions had been met, and if 
not, the doses were reduced.  If toxicities had not settled after a delay of 2 weeks or more, 
the patient was removed from the study. 
Concomitant therapies 
Anti-emetic and other supportive drugs, including atropine, were prescribed according to 
local treatment guidelines.  It was recommended that patients experiencing severe 
diarrhoea receive loperamide, 2 tablets every 4–6 hours, until diarrhoea had not occurred 
for 12 hours. 
Statistical analyses 
Response rates, progression-free survival, and overall survival were analysed on the basis 
of intention to treat.  Analysis of response rates used chi-squared tests for comparing 
proportions, or Leibermeister tests if cell counts were less than 5.  Secondary analysis of 
toxicity from diarrhoea was adjusted for time on treatment using generalised linear 
models (log-log link function) with an exposure time offset.  Survival endpoints were 
summarised with Kaplan-Meier estimates and compared using log-rank tests. 
We compared quality of life by measuring the change in score from baseline until 
progression and comparing change scores with two sample t-tests. 
Systematic review method 
We systematically searched the following electronic databases and abstract collections 
for randomised trials of the same or similar second-line treatment as ours: MEDLINE 
(1950–January 2010), EMBASE (1980–January 2010), and the Cochrane Central 
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Register of Controlled Trials (CENTRAL), the American Society of Clinical Oncology 
(1998–2010), and the European Society of Medical Oncology (2002–1010). Citation lists 
were searched for additional references. No restrictions, such as language, were applied. 
Trials assessing second-line irinotecan (alone or in combination with both leucovorin and 
5-fluorouracil) in advanced colorectal cancer previously treated with 5-fluorouracil-based 
regimens were considered for inclusion.  Retrospective studies and trials where 5-
fluorouracil was administered as bolus only were excluded, since 5-fluorouracil 
administered as a bolus followed by IV infusion has a sufficiently different toxicity 
profile. 
Three authors (SY, CB and SC) independently screened the results of the literature 
review. One author extracted the relevant data from the shortlisted trials, and a second 
author double-checked the results.  All outcomes used in our study were investigated: 
rates of grade 3/4 diarrhoea, rates of other grade 3/4  toxicities, quality of life, response 
rates, progression-free survival and overall survival 
Randomised comparisons were combined using fixed-effects models weighted by inverse 
variance.  Many clinically heterogeneous single-arm studies were expected, and therefore, 
pooled estimates were calculated for each arm separately. 
Results 
Between June 2005 and January 2008, 89 patients were randomised (Figure 1). 
Recruitment was slower than had been expected, which contributed to the trial being 
stopped before the planned 100 patients had been enrolled.  The study arms were well 
balanced except that more men and fewer patients with chemotherapy-free interval longer 
than 6 months were allocated to the combination-therapy arm (Table 1).  All patients had 
received previous chemotherapy with a fluoropyrimidine, and some patients had had 
more than one previous line of treatment. 
Four patients withdrew from the study early.  Three withdrew before having baseline 
tumour assessments and did not receive any treatment.  The fourth patient opted 3 days 
after consent to receive off-study irinotecan plus cetuximab. One of the four patients 
explicitly withdrew consent for their data to be used in the study and was not included in 
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any analysis. The other three patients were included in the analysis but censored at the 
time of withdrawal. 
All other patients received at least 1 cycle of protocol treatment. Median time on 
treatment was 3.2 months on single agent compared with 4.4 months on combination 
(Table 2). Over 95% of planned doses were administered, but 66% of patients on the 
combination arm and 41% of patients receiving single-agent irinotecan experienced at 
least one treatment delay. 
Toxicity  
Eight patients in the single-agent arm and 4 in the combination-therapy arm had grade 3 
or 4 diarrhoea. This was not a statistically significantly difference (odds ratio (OR) 0.46; 
95% confidence interval (95%CI) 0.13–1.67, P=0.24). When adjustment was made for 
the longer time on treatment for combination therapy, the observed rate of grade 3+ 
diarrhoea appeared lower than for single-agent treatment, but the difference remained 
non-significant after this adjustment (OR 0.34; 95%CI 0.10–1.13; P=0.08). (Tables 3 and 
4). The only statistically significant non-haematological toxicity difference was complete 
alopecia (OR 0.28; 95%CI 0.10–0.81; P=0.02), which was more frequent in the patients 
receiving irinotecan alone. Some toxicities had a higher incidence in the combination arm. 
Serious haematological toxicity was uncommon, and incidence similar in both the arms.  
Tumour response and survival 
No patient completely responded to treatment. Five patients in each treatment arm had a 
partial response (Table 4). Thirty-one patients in each arm had a best response rate of 
stable disease. 
With median follow-up of 37 months, the median progression-free survival for patients in 
the single-agent arm was 4.0 months and in the combination arm was 6.2 months (Figure 
2). The median survival for single-agent was 11.2 months and in the combination arm 
was 15.4 months. There was no statistically significant difference between the treatment 
arms in progression-free survival (p=0.34) or overall survival (p=0.14). 
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Quality of life 
Quality of life questionnaire completion was reasonable at baseline (83%) but diminished 
during treatment (6 weeks 69%, 12 weeks 52%, 18 weeks 62%, 24 weeks 58%).  
Baseline scores were similar in both groups except for worse diarrhoea (6.0 vs. 15.7) and 
financial difficulties (8.6 vs. 20.0) in the combination arm.  After treatment, in the single-
agent arm, patients rated diarrhoea and nausea and vomiting significantly worse than at 
baseline.  In the combination arm, there was a statistically significant worsening in 
patients’ rating of nausea and vomiting, constipation and overall quality of life (Figure 4). 
For all other scales there was no evidence of a significant effect of treatment on quality of 
life. None of the changes in quality of life from baseline were significantly different 
between the two treatment arms. 
Systematic review 
Twenty-nine clinical trials with a second-line irinotecan treatment arm, alone or in 
combination with both leucovorin and 5-fluorouracil were found (; ; 8-10, 16-41 Of these, 
two were randomised controlled trials comparing single-agent irinotecan with irinotecan 
in combination.36, 38  Seymour et al. provided significant evidence of a reduction in 
diarrhoea for those receiving second-line combination treatment.38  These patients were 
randomised before first-line treatment, and so comparisons of second-line treatments 
represent non-randomised comparisons since results cannot be adjusted for potential bias 
due to variable experiences with the earlier treatments.  The study by Graeven et al. used 
a weekly regimen of irinotecan in both treatment arms but apart from this difference 
provides an unbiased comparison.36 Analysis of other studies using irinotecan-based 
therapy was hampered by substantial variation in doses and schedules of regimens used.  
Results of DaVINCI were consistent with those of the other studies (Table 5). In the trial 
reported by Seymour et al., the pooled odds ratio for reduction in the incidence of 
diarrhoea associated with combination therapy compared with single-agent irinotecan 
was 0.45 (95% CI 0.30–0.75).38 The response rate for patients receiving the combination 
was higher (16.2 vs. 10.7%), although this difference was not statistically significant. 
There was no difference in progression-free survival (4.4 vs. 4.3 months). In the study 
reported by Graeven et al., there was a non-statistically significant higher, rate of 
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diarrhoea in the single-agent arm (18.5 vs. 10.7%).36  Response rates were similar (15.8 
vs. 15.0%), progression-free survival was 3.7 months in both arms, and overall survival 
was 9.5 months (combination) and 10.7 months (single agent). Data from the non-
randomised studies were consistent with these findings (Table 5 and Figure 5). 
Discussion 
In the treatment of patients with metastatic colorectal cancer, these two commonly used 
and previously not compared, second-line irinotecan-containing treatment options had 
essentially similar efficacy in the DaVINCI trial. Response rate, progression-free survival, 
and overall survival were statistically similar, which is consistent with previous studies. 
The slightly longer progression-free survival and overall survival among patients on 
combination therapy was possibly because of patient selection. While there was more 
diarrhoea and nausea and vomiting in patients receiving irinotecan only, the only 
significant toxicity difference was for alopecia, which was worse in the irinotecan arm. 
These data are consistent with the findings of a meta-analysis of other randomised and 
non-randomised trials. There were no significant differences in changes in QOL over 
time, or from baseline, between the two study treatments. Although some individual 
quality of life indices, including diarrhoea, favoured the combination arm, patients in the 
single-agent arm experienced better global quality of life. 
Thus, there does not appear to be the same synergy between irinotecan and 5-fluorouracil 
with leucovorin as there is between oxaliplatin and fluoropyrimidines. In the study 
reported by Rothenberg et al. comparing the combination of 5-fluorouracil and 
oxaliplatin with each agent alone as second-line therapy, the response rate and time to 
progression were higher for the oxaliplatin combination.7 Nonetheless, the combination 
treatment in DaVINCI, with its comparatively better toxicity profile to single-agent 
irinotecan, was not associated with any worsening of clinical outcomes. 
The DaVINCI results are consistent with those of other studies that assessed irinotecan 
with or without 5-fluorouracil plus leucovorin. Findings from our systematic review also 
suggested equivalence of these 2 therapeutic options, albeit with a greater incidence of 
severe diarrhoea (approximately double) and alopecia in the single-agent arms. However, 
lower toxicity in the combination arm did not compromise tumour response, progression-
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free survival or overall survival. The DaVINCI results are consistent with those of the 
Medical Research Council Fluorouracil, Oxaliplatin and Irinotecan: Use and Sequencing 
(MRC FOCUS) trial, which also found slightly longer survival in the irinotecan 
combination arms.38 
In spite of a simple design, DaVINCI accrued patients more slowly than expected, which 
led to early closure. One possible explanation is that many medical oncologists were keen 
to treat their patients with molecular targeted agents, even in the absence of evidence at 
the time.   
The observed differences in toxicity between the two arms may be confounded by the 
differences in irinotecan scheduling and dose.  For some patients the toxicity profile of 
the combination arm may be preferable despite similar efficacy. Those with pre-existing 
diarrhoea may not wish to risk the modest increase in severe diarrhoea that accompanies 
single-agent treatment, especially patients receiving concomitant EGFR-inhibiting 
antibodies, the use of which is frequently complicated by diarrhoea.42-43 Similarly, many 
patients might choose to avoid a greater risk of total alopecia. For others, the efficacy of 
the single-agent arm means that a central venous catheter can be avoided and they can be 
treated on a more convenient 3-weekly schedule.  Furthermore, the limitations in 
evaluating the combined data — the use of non-randomised trial comparisons, that the 
DaVINCI trial in isolation was not powered to show significant differences in most 
outcomes, and that toxicity differences may be confounded by irinotecan scheduling and 
dose — should not exclude the consideration of use of single-agent irinotecan as a 
treatment option. 
In summary, both single agent irinotecan and irinotecan in combination with infusional 5-
fluorouracil are acceptable second-line treatments for patients with advanced or 
metastatic colorectal cancer.  Toxicity was slightly greater in the single-agent irinotecan 
arm, but it should not be ruled out as a treatment option. Based on our results, we feel 
comfortable recommending that this choice of treatment be made based on personal 
preference. 
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Figure legends 
Figure 1 
Enrolment and analysis of patients in the DaVINCI study 
Figure 2 
Kaplan-Meier graph of progression-free survival in the two study arms. 
Figure 3 
Kaplan-Meier graph of overall survival in the two study arms. 
Figure 4 
Change in score from baseline until treatment progression. Positive changes represent 
improvement in quality of life 
Figure 5 
Proportions of patients with grade 3 or 4 diarrhoea for single-arm trials of irinotecan (top 
panel) or combination therapy including irinotecan (bottom panel) in studies identified in 
systematic review. Irinotecan dosage (mg), length of cycle (days) are shown. 
 
 
Da Vinci 16-Sep-10 15 
References 
1. Aschele C, Bergamo F, Lonardi S. Chemotherapy for operable and advanced 
colorectal cancer. Cancer Treat Rev. 2009;35(6):509-16. 
2. Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. 
Randomized phase III study of capecitabine plus oxaliplatin compared with 
fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal 
cancer. J Clin Oncol. 2008 Apr 20;26(12):2006-12. 
3. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. 
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in 
metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008 Apr 
20;26(12):2013-9. 
4. Sobrero A, Ackland S, Clarke S, Perez-Carrion R, Chiara S, Gapski J, et al. Phase 
IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and 
irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology. 
2009;77(2):113-9. 
5. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, 
et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl 
J Med. 2008 Oct 23;359(17):1757-65. 
6. Bouche O, Beretta GD, Alfonso PG, Geissler M. The role of anti-epidermal 
growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic 
colorectal cancer. Cancer Treat Rev. 2010 Feb;36 Suppl 1:S1-10. 
7. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, 
et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy 
alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-
leucovorin: interim results of a phase III trial. J Clin Oncol. 2003 Jun 1;21(11):2059-69. 
8. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, et al. 
Randomised trial of irinotecan plus supportive care versus supportive care alone after 
fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998 Oct 
31;352(9138):1413-8. 
9. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, et al. 
Randomised trial of irinotecan versus fluorouracil by continuous infusion after 
fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998 Oct 
31;352(9138):1407-12. 
10. Frontini L, Labianca R, Sobrero A, Rosso R, Turci D, Pergola M, et al. Irinotecan 
(CPT-11) Is Effective as Second-Line Chemotherapy in Advanced Colorectal Cancer 
(ACC): A Phase II Trial of GISCAD (Italian Group for the Study of Gastrointestinal 
Cancer). Proc Am Soc Clin Oncol. 1999;18:Abstract 1000. 
11. Bittoni A, Pistelli M, Scartozzi M, E G, R B, S C. Second-line chemotherapy with 
irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric 
cancer: lessons from the clinical practice. Annals of Oncology. 2009;20 (Suppl 8):viii62 - 
D22. 
Da Vinci 16-Sep-10 16 
12. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. 
Cardiovascular events associated with rofecoxib in a colorectal adenoma 
chemoprevention trial. N Engl J Med. 2005 Mar 17;352(11):1092-102. 
13. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The 
European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life 
instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 
1993;85(5):365-76. 
14. Stockler MR, O'Connell R, Nowak AK, Goldstein D, Turner J, Wilcken NR, et al. 
Effect of sertraline on symptoms and survival in patients with advanced cancer, but 
without major depression: a placebo-controlled double-blind randomised trial. Lancet 
Oncol. 2007 Jul;8(7):603-12. 
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et 
al. New guidelines to evaluate the response to treatment in solid tumors. European 
Organization for Research and Treatment of Cancer, National Cancer Institute of the 
United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000 Feb 
2;92(3):205-16. 
16. Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA, 3rd, Nelson J, Hilsenbeck SG, 
et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent 
colorectal cancer. J Clin Oncol. 1996 1996;14(4):1128-35. 
17. Pitot HC, Wender DB, O'Connell MJ, Schroeder G, Goldberg RM, Rubin J, et al. 
Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol. 
1997 1997;15(8):2910-9. 
18. Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, et al. Phase II study 
of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive 
patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol. 1997 
1997;15(1):251-60. 
19. Ang PCS, Koo WH, Au E, Ang PT, Khoo KS. Phase II Study of Irinotecan (CPT-
11) in patients with 5-Fluorouracil-refractory metastatic colorectal carcinoma - An Asian 
experience. Ann Oncol. 1998;9 (suppl 4):45 Abstract 212. 
20. Antón AE, Marcuello E, Massutí B, Carrato A, Abad A, Cervantes A, et al. The 
experience of the TTD Spanish Cooperative Group in advanced colorectal cancer 
resistant to 5-FU with irinotecan (CPT-11) on a 3 weeks schedule: Final results. 23rd 
Congress of the European Society for Medical Oncology (ESMO). . Ann Oncol 
1998;9(Supp4):184. 
21. Lara MA, Feliu J, Salinas P, Fernandez Y, Garcia-Giron C. Irinotecan (CPT-11) 
in pretreated metastatic colorectal cancer (CRC). Ann Oncol. 1998;9 (Suppl 4):45  
Abstract 215. 
22. Aravantinos G, Skarlos DV, Kosmidis P, Georgoulias V, Sgouros I, Bafaloukos D, 
et al. Irinotecan (CPT-11) in patients with advanced colorectal cancer previously treated 
with 5-fluorouracil-based chemotherapy. Crit Rev Oncol Hematol. 1999 Dec;32(3):209-
19. 
Da Vinci 16-Sep-10 17 
23. Hoeffken K, Ridwelsky C, Wein A, Mezger J, Stoffregen C, Weber B, et al. 
Phase II Study of Irinotecan as Second Line Chemotherapy (CT) in Metastatic Colorectal 
Cancer (CRC). (Meeting abstract). Proc Am Soc Clin Oncol. 1999;18:Abstract 937  
24. Rothenberg ML, Cox JV, DeVore RF, Hainsworth JD, Pazdur R, Rivkin SE, et al. 
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously 
treated colorectal carcinoma. Cancer. 1999 1999 Feb;85(4):786-95. 
25. Van Cutsem E, Cunningham D, Ten Bokkel Huinink WW, Punt CJA, 
Alexopoulos CG, Dirix L, et al. Clinical activity and benefit of irinotecan (CPT-11) in 
patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). Eur J Cancer. 
1999;35(1):54-9. 
26. Schöffski P, Vanhoefer U, Kirchner H, Trenn G, Bokemeyer C, Preusser P, et al. 
Phase II study of irinotecan as second line chemotherapy in metastatic colorectal cancer 
after prior exposure to infusional 5-FU-based chemotherapy. Proc Am Soc Clin Oncol. 
2000;19(Abstract 1155). 
27. Gil-Delgado MA, Guinet F, Castaing D, Adam R, Coeffic D, Durrani AK, et al. 
Prospective phase II trial of iriontecan, 5-fluorouracil, and leucovorin in combination as 
salvage therapy for advanced colorectal cancer. Am J Clin Oncol. 2001 Feb;24(1):101-5. 
28. Leonard P, Seymour MT, James R, Hochhauser D, Ledermann JA. Phase II study 
of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de 
Gramont) for first or second line treatment of advanced or metastatic colorectal cancer. 
Br J Cancer. 2002 Nov 18;87(11):1216-20. 
29. Tsavaris NB, Polyzos A, Gennatas K, Kosmas C, Vadiaka M, Dimitrakopoulos A, 
et al. Irinotecan (CPT-11) in patients with advanced colon carcinoma relapsing after 5-
fluorouracil-leucovorin combination. Chemotherapy. 2002 May;48(2):94-9. 
30. Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR. Phase III 
comparison of two irinotecan dosing regimens in second-line therapy of metastatic 
colorectal cancer. J Clin Oncol. 2003 Mar 1;21(5):807-14. 
31. Mendez M, Salut A, Garcia-Giron C, Navalon M, Diz P, Garcia Lopez MJ, et al. 
A multicenter phase II study of irinotecan in patients with advanced colorectal cancer 
previously treated with 5-fluorouracil. Clin Colorectal Cancer. 2003 Nov;3(3):174-9. 
32. Tsavaris N, Ziras N, Kosmas C, Giannakakis T, Gouveris P, Vadiaka M, et al. 
Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal 
carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized 
study. Cancer Chemother Pharmacol. 2003 Dec;52(6):514-9. 
33. Lal R, Dickson J, Cunningham D, Chau I, Norman AR, Ross PJ, et al. A 
randomized trial comparing defined-duration with continuous irinotecan until disease 
progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced 
colorectal cancer. J Clin Oncol. 2004 Aug 1;22(15):3023-31. 
34. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. 
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: 
a randomized GERCOR study. J Clin Oncol. 2004 Jan 15;22(2):229-37. 
Da Vinci 16-Sep-10 18 
35. Garcia-Giron C, Garcia Palomo A, Alonso Lopez C, Leon Carbonero A, Mendez 
Urena M, Adrover Cebrian E, et al. Phase II trial of fortnightly irinotecan (CPT-11) in the 
treatment of colorectal cancer patients resistant to previous fluoropyrimidine-based 
chemotherapy. Clin Transl Oncol. 2005 Jul;7(6):244-9. 
36. Graeven U, Arnold D, Reinacher-Schick A, Heuer T, Nusch A, Porschen R, et al. 
A randomised phase II study of irinotecan in combination with 5-FU/FA compared with 
irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma. 
Onkologie. 2007 Apr;30(4):169-74. 
37. Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, et al. 
Sequential versus combination chemotherapy with capecitabine, irinotecan, and 
oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled 
trial. Lancet. 2007 Jul 14;370(9582):135-42. 
38. Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, et 
al. Different strategies of sequential and combination chemotherapy for patients with 
poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. 
Lancet. 2007 Jul 14;370(9582):143-52. 
39. Tsavaris N, Kosmas C, Skopelitis H, Papadoniou N, Polyzos A, Zografos G, et al. 
Sequential administration of 5-fluorouracil (5FU)/leucovorin (LV) followed by irinotecan 
(CPT-11) at relapse versus CPT-11 followed by 5-FU/LV in advanced colorectal 
carcinoma. A phase III randomized study. Chemotherapy. 2007;53(4):282-91. 
40. Haller DG, Rothenberg ML, Wong AO, Koralewski PM, Miller WH, Jr., Bodoky 
G, et al. Oxaliplatin plus irinotecan compared with irinotecan alone as second-line 
treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. 
J Clin Oncol. 2008 Oct 1;26(28):4544-50. 
41. Kim GP, Sargent DJ, Mahoney MR, Rowland KM, Jr., Philip PA, Mitchell E, et 
al. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and 
leucovorin in patients with advanced colorectal carcinoma previously treated with 
fluorouracil: N9841. J Clin Oncol. 2009 Jun 10;27(17):2848-54. 
42. Jean G, Shah S. Epidermal growth factor receptor monoclonal antibodies for the 
treatment of metastatic colorectal cancer. Pharmacotherapy 2008 28(6):742-54. 
43. Ouwerkerk J, C. B-D. Best practices in the management of toxicities related to 
anti-EGFR agents for metastatic colorectal cancer. 
. Eur J Oncol Nurs. 2010;14(4):337-49. 
 
 
Da Vinci 17-Dec-10 1 
Table 1 Baseline characteristics, by treatment group 
 Irinotecan Combination  
Characteristics % (n=44
#
) % (n=44) 
Sex male 59 70 
ECOG performance status   
 0 or 1 98 93 
 2 2 7 
Chemotherapy-free >6 months  20 15 
Baseline diarrhoea * 9.1 6.8 
Primary site    
 colon 67 61 
 rectum 33 39 
Metastases    
 liver 68 66 
 lung 52 61 
 lymph 39 43 
 bone 5 7 
 other 39 32 
Tumour grade    
 1 5 11 
 2 61 52 
 3 16 27 
 unknown 18 9 
Previous treatment†   
 radiotherapy 30 27 
 oxaliplatin 70 77 
 5-fluorouracil 63 73 
 capecitabine 53 48 
 bevacizumab 23 25 
 mitomycin C 5 2 
 panitumumab 2 0 
Median age (range) (years) 66 (26–84) 64 (35–78) 
Median years since diagnosis of 
advanced disease (range) 
1.1 (0.1–2.8) 1.0 (0.0–5.9) 
Laboratory values (median)   
 neutrophils (10
9
/L) 4.80 4.95 
 platelets (10
9
/L) 269 219 
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 Irinotecan Combination  
Characteristics % (n=44
#
) % (n=44) 
 haemoglobin (g/dL) 13.5 12.8 
 serum creatinine (xULN) 0.70 0.75 
 bilirubin (xULN) 0.50 0.50 
#  1 patient withdrew consent, not included in analysis 
* All grade 1. 
†  All patients had prior chemotherapy. 
ULN - Upper limit of normal. 
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Table 2 Treatment characteristics, by treatment group  
 Irinotecan Combination  
Treatment received % (n=43) % (n=42) 
Average proportion of initial dose    
 irinotecan 96 96 
 5-fluorouracil bolus — 95 
 5-fluorouracil infusion — 97 
 leucovorin — 99 
Anti-diarrhoea medication 47 47 
Reason for stopping treatment    
    Tumour progression 61 39 
    Patient preference 18 14 
    Clinician preference 7 14 
    Toxicity 5 11 
    Death 7 5 
    Other 2 14 
Median duration of treatment (mths) 3.2 4.4 
Median treatment delay (days)  4.5   7.0 
Any treatment delay 41 66 
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Table 3 Numbers of patients with grade 3 or 4 toxicity, by treatment 
 Irinotecan Combination  
Toxicity n=43 (%) n=42 (%) 
Diarrhoea 8 (19) 4 (10) 
Nausea 3 (7) 1 (2) 
Vomiting 2 (5) 2 (5) 
Stomatitis 0 (0) 1 (2) 
Fatigue 4 (9) 4 (10) 
Alopecia* 16 (37) 6 (14) 
Neutropenia, no infection 2 (5) 6 (14) 
Febrile neutropenia 3 (7) 1 (2) 
* Grade 2. 
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Table 4 Primary and secondary endpoints, by treatment group 
Endpoint Irinotecan  Combination Comparison (95% CI) P-Value 
Diarrhoea, grade 3 or 4 (%)* 18.6 9.5 OR=0.46 (0.13–1.67) 0.24 
Alopecia, grade 2 (%) 37.2 14.2 OR=0.28 (0.10–0.81) 0.02 
Any grade 3 or 4 toxicity (%) 48.8 47.6 OR=0.95 (0.41–2.23)  
Partial tumour response (%) 11.4 (3.7–24.6) 11.4 (3.7–24.6) OR=1.00 (0.27–3.73) 0.99 
Median progression-free 
survival (months) 
4.0  (2.7–5.7) 6.2 (5.4–6.7) HR=0.81 (0.52–1.25) 
0.34 
Median overall survival 
(months) 
11.2  (8.3–13.3) 15.4 (8.1–19.3) HR=0.72 (0.46–1.12) 
0.14 
*Analysis adjusted for time on treatment: OR = 0.34 (0.10 - 1.13), p=0.08 
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Table 5 Systematic review including DaVinci and two other randomised trials of irinotecan 
compared with combination therapy, and 27 single-arm trials of irinotecan or combination 
therapy 
 
Estimates of effect in randomised 
trials* 
Rates of toxicity (%) in all trials, 
including single-arm trials 
Endpoint 
No. 
studies Estimate (95%CI) Irinotecan Combination 
Diarrhoea, grade 3 or 4 3
a,b,c
 OR=0.45 (0.27–0.75) 23.5 (20– 27) 8.4 (6– 11) 
Alopecia, grade 2 2
 a,b
 OR=0.28 (0.13–0.60) 38.9 (25– 53) 11.7 (4– 19) 
Tumour response 3
 a,b,c
 OR=0.68 (0.43–1.08) 12.5 (11– 14) 14.2 (7– 21) 
Median progression-
free survival at 3 
months (%) 
3
 a,b,c
 HR=0.96 (0.84–1.09) 60.4 (55– 66) 62.2 (51– 73) 
Median overall survival 
at 6 months (%) 
3
 a,b,c
 HR=0.92 (0.51–1.67)  71.4 (69– 74) 76.1 (63– 90) 
*  For irinotecan compared with combination therapy in three trials: 
a
DaVINCI, 
b
Seymour et al
1
 and 
c
Graeven et al
2
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Figure 1 – Consort diagram 
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Figure 2 - DaVinci Progression-free survival 
months from randomisation
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Time from randomisation to progression or death.  HR=0.81 (0.52–1.25) p=0.34 
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Figure 3 - Da Vinci Overall Survival 
months from randomisation
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Time from randomisation to death by any cause.  HR = 0.72 (0.46–1.12), p=0.14.  
 
Da Vinci 17-Dec-10 10 
Figure 4 - Quality of life  
 
 
Da Vinci 17-Dec-10 11 
Figure 5 – Summary of study grade 3/4 diarrhoea estimates  
Diarrhoea (Single)
Proportion patients with Grade 3/4
S
tu
d
y
 R
e
fe
re
n
c
e
-0.1 0.0 0.1 0.2 0.3 0.4 0.5
1996 Rothenberg      18 / 48
1997 Pitot                  44 / 90
1997 Rougier            64 / 130
1998 Ang                   10 / 26
1998 Cunningham    42 / 189
1998 Rougier            29 / 133
1999 Aravantinos       9 / 62
1999 Frontini            41 / 77
1999 Rothenberg     34 / 64
1999 Rothenberg     11 / 102
1999 Van Cutsem    26 / 107
2000 Schoffski         24 / 108
2003 Fuchs               34 / 95
2003 Fuchs               36 / 196
2003 Mendez            22 / 115
2005 Garcia-Giron   12 / 64
2007 Graeven             5 / 27
2007 Seymour          58 / 364
2008 Haller               70 / 310
2009 Kim                  76 / 245
2010 Current Study     8 / 45
Summary
 
Diarrhoea (Combination)
Proportion patients with Grade 3/4
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n
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e
-0.1 0.0 0.1 0.2 0.3 0.4 0.5
2001 Gil-Delgado    3 / 39
2002 Leonard          2 / 36
2004 Tournigand      8 / 69
2007 Graeven          3 / 28
2007 Seymour        14 / 185
2010 Current Study   4 / 44
Summary
 
Da Vinci 17-Dec-10 12 
Web Appendix Figure 6 
Study
DaVinci    (n=88)
Graven     (n=55)
Seymour* (n=549)
Summary
Median
(single)
4.0
3.7
4.3
Median
(comb)
6.2
3.7
4.4
HR
0.81
0.87
0.98
0.96
0.4 0.6 0.8 1.0 1.2 1.4 1.6
* HR estiamted from medians, CI estiamted from published test statistic.
Progression free survival
 
Patients with Grade3/4 diarrhoea
Odds Ratio
S
tu
d
y
 R
e
fe
re
n
c
e
0.16 0.25 0.40 0.63 1.00 1.58 2.51
DaVinci   4/44       8/45
Graven    3/38         5/27
Seymour  14/285    58/364
Summary
 
 
 
 
